CSDE Affiliate Susan M. Graham (Medicine and Global Health) and co-authors recently published a study of depressive symptoms, HIV vulnerability and oral PrEP use and adherence among adolescent girls and young women in Western Kenya in BMJ Open. Graham and co-authors surveyed 300 females aged 19-24 who attended follow-up visits in a randomized controlled trial of a single-dose HPV vaccine. Moderate to severe depressive symptoms were reported by 14%. Factors associated with depressive symptoms included medium HIV risk perception and engaging in transactional sex. The rate of oral PrEP use was 19%, with 43% reporting 5+ doses in the past week. Depressive symptoms were not significantly associated with PrEP use. First author, Dismas Congo Ouma, led this work as part of his thesis while a UW Global Health MPH student, advised by Graham.